Get the Stockscreener App
1.96
2.62%
0.05
Inovio Pharmaceuticals Inc stock is traded at $1.96, with a volume of 2.28M.
It is up +2.62% in the last 24 hours and up +35.17% over the past month.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
See More
Previous Close:
$1.91
Open:
$1.93
24h Volume:
2.28M
Relative Volume:
1.27
Market Cap:
$104.16M
Revenue:
$832.00K
Net Income/Loss:
$-135.12M
P/E Ratio:
-0.3218
EPS:
-6.09
Net Cash Flow:
$-124.69M
1W Performance:
+5.38%
1M Performance:
+35.17%
6M Performance:
-12.50%
1Y Performance:
-73.48%
1-Day Range:
$1.90
$2.055
1-Week Range:
$1.79
$2.055
52-Week Range:
$1.30
$7.76
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Name
Inovio Pharmaceuticals Inc
Sector
Industry
Phone
(858) 410-3134
Address
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.96 | 100.97M | 832.00K | -135.12M | -124.69M | -6.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Piper Sandler | Overweight |
| May-14-24 | Initiated | Stephens | Overweight |
| Jan-25-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-09-22 | Downgrade | Maxim Group | Buy → Hold |
| Nov-01-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-19-22 | Resumed | RBC Capital Mkts | Sector Perform |
| May-11-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-29-21 | Resumed | Jefferies | Hold |
| Sep-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-24-21 | Initiated | Jefferies | Hold |
| Mar-23-21 | Initiated | BofA Securities | Neutral |
| Feb-12-21 | Initiated | Oppenheimer | Outperform |
| Nov-17-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Nov-10-20 | Upgrade | ROTH Capital | Sell → Neutral |
| Sep-28-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-28-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-01-20 | Downgrade | Maxim Group | Buy → Hold |
| Jul-01-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Jun-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-26-20 | Downgrade | Stifel | Buy → Hold |
| May-21-20 | Initiated | The Benchmark Company | Buy |
| Apr-30-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Mar-13-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-13-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-19-19 | Initiated | ROTH Capital | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
| Oct-18-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Initiated | Citigroup | Buy |
| Jun-08-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-24-17 | Reiterated | Maxim Group | Buy |
| Mar-16-17 | Upgrade | Maxim Group | Hold → Buy |
| Mar-16-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
View All
Inovio Pharmaceuticals Inc Stock (INO) Latest News
INOVIO Advances Toward FDA Filing for INO-3107 as Quarterly Losses Narrow - MSN
Inovio Pharmaceuticals (NASDAQ:INO) Given "Neutral" Rating at HC Wainwright - MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO) Stock Rating Lowered by Wall Street Zen - MarketBeat
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Cervical Dysplasia Treatment Market Size Report 2034, - openPR.com
Inovio aims for BLA submission and FDA file acceptance by year-end 2025 as 3107 data shows sustained surgery reduction - MSN
Inovio Pharmaceuticals Inc. Recovery Linked to Earnings Surprise2025 Market Sentiment & Real-Time Buy Signal Alerts - newsyoung.net
Momentum Screeners Rank Inovio Pharmaceuticals Inc. in Top 5 TodayLong Setup & Low Risk Entry Point Guides - newsyoung.net
Inovio Pharmaceuticals: Hold Rating Amid Financial Challenges and Competitive Pressures - AInvest
INOVIO to Announce Q2 2025 Results on August 12 - MSN
INO.O Surges 13.9%: What's Behind Inovio Pharmaceuticals’ Intraday Spike? - AInvest
Inovio Pharmaceuticals shares surge 22.84% intraday after Q2 earnings report, BLA submission plan, and rating upgrade. - AInvest
Inovio Pharmaceuticals (INO) Surges 19.4% on Earnings Optimism—What's Fueling the Biotech Rally? - AInvest
Inovio Pharmaceuticals Soars 12.28% on Q2 Earnings, Clinical Progress - AInvest
Inovio Pharmaceuticals Second Quarter 2025 Earnings: US$0.61 loss per share (vs US$1.19 loss in 2Q 2024) - Yahoo Finance
Inovio rises after promising Q2 results - MSN
Inovio Pharmaceuticals : Second Quarter 2025 Financial Results Conference Call Q2 2025 Financial Results Presentation - MarketScreener
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment - The Globe and Mail
H.C. Wainwright Maintains Inovio Pharmaceuticals(INO.US) With Hold Rating, Maintains Target Price $3 - 富途牛牛
Inovio Pharmaceuticals: HC Wainwright Raises PT to $3 from $3, Maintains Neutral Rating. - AInvest
Inovio Pharmaceuticals’ SWOT analysis: dna immunotherapy firm’s stock faces pivotal year By Investing.com - Investing.com South Africa
Inovio Pharmaceuticals’ SWOT analysis: dna immunotherapy firm’s stock faces pivotal year - Investing.com
Inovio Pharmaceuticals Q2 2025 Earnings Call Highlights: BLA Submission, Financial Challenges, and Regulatory Progress - AInvest
Inovio Pharmaceuticals Inc. Stock Rallies 14.1%, Outperforms Competitors - 富途牛牛
Inovio Pharmaceuticals shares rise 13.76% intraday after reporting Q2 2025 financial results and progress on INO-3107. - AInvest
Inovio Pharmaceuticals Q2 Results: Net Loss Narrows to $0.61 per Share - AInvest
Inovio rises after promising Q2 results (INO:NASDAQ) - Seeking Alpha
Jefferies Upgrades Inovio Pharmaceuticals(INO.US) to Buy Rating, Cuts Target Price to $1.8 - 富途牛牛
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q2 2025 Earnings Call Transcript - Insider Monkey
Jefferies lowers Inovio stock price target to $1.80 from $2.00 By Investing.com - Investing.com Canada
JMP analyst reiterates Market Outperform rating on Inovio stock By Investing.com - Investing.com Canada
Inovio Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Inovio Pharmaceuticals (INO) Targets BLA Submission for INO-3107 by Year-End 2025 - GuruFocus
INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights - BioSpace
Inovio’s 2025Q2 Earnings Call: Key Contradictions on Regulatory Strategy, Financial Health, and Clinical Trials - AInvest
Inovio Targets BLA Submission, FDA Approval by Year-End 2025 Amid Positive 3107 Trial Results - AInvest
Inovio Pharmaceuticals Inc (INO) Q2 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Inovio Pharmaceuticals Inc (INO) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus
Inovio Pharmaceuticals Reports Q2 2025 Financial Progress - TipRanks
Inovio Pharmaceuticals 2025 Q1 Earnings Net Loss Narrows 35.4% - AInvest
Inovio: Q2 Earnings Snapshot - Big Rapids Pioneer
Earnings call transcript: Inovio’s Q2 2025 sees reduced losses, stock rises - Investing.com
Transcript : Inovio Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
Inovio Pharmaceuticals Inc Reports Q2 2025 EPS of -$0.61, Narrow - GuruFocus
INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025 - Eastern Progress
INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights | INO Stock News - GuruFocus
Inovio Pharmaceuticals Inc Reports Q2 2025 EPS of -$0.61, Narrowly Beating Estimates - GuruFocus
INOVIO on track to submit BLA for INO-3107 in 2H25, FDA requested rolling submission. - AInvest
INOVIO Reports Second Quarter 2025 Financial Results And Recent Business Highlights - Barchart.com
Major Earnings Expected After the Close Tuesday: CoreWeave, Inovio Pharmaceuticals, Luminar Technologies, and More - AInvest
Options Volatility and Implied Earnings Moves Today, August 12, 2025 - TipRanks
Inovio Pharmaceuticals Inc Stock (INO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):